Lund, Sweden — 20 December 2023 — Camurus (NASDAQ STO: CAMX) today announced that the company will be moved from the Mid Cap to the Large Cap segment on the Nasdaq Stockholm stock exchange effective January 2, 2024. The change follows Nasdaq’s annual review of its Nordic market capitalization (market cap) segments.1
"The move to the Large Cap on Nasdaq Stockholm is a reflection of Camurus’ financial performance, commercial growth and progress in the R&D pipeline of innovative medications", said Fredrik Tiberg, President & CEO. “Camurus is committed to developing and making new and effective treatments accessible for patients with severe and chronic diseases in areas with high unmet medical needs”.
For more information
Fredrik Tiberg, President & CEO
Tel. +46 (0)46 286 46 92
fredrik.tiberg@camurus.com
Fredrik Joabsson, Chief Business Development Officer
Tel. +46 (0)70 776 17 37
ir@camurus.com
About Camurus
Camurus is a Swedish science-led biopharmaceutical company committed to developing and commercializing innovative and differentiated medicines for the treatment of severe and chronic conditions. New drug products with best-in-class potential are conceived based on the company’s proprietary FluidCrystal® drug delivery technologies and its extensive R&D expertise. Camurus’ clinical pipeline includes products for the treatment of dependence, pain, cancer, and endocrine disorders, developed in-house and in collaboration with international pharmaceutical companies. The company’s shares are listed on Nasdaq Stockholm under the ticker CAMX. For more information, visit www.camurus.com.
Reference
- Nasdaq, Market Cap Segment Review at Nasdaq Nordic Exchanges. Published 20 December, 2023.
This information was submitted for publication at 1:45 pm CET on 20 December 2023.